Editas EVP Ory Daniel Scott Receives 950,000-Share Award

What Happened Ory Daniel Scott, Executive Vice President and Chief Medical Officer of Editas Medicine (EDIT), was granted an equity award (reported as an option) for 950,000 shares on September 8, 2026. The grant is reported at $0.00 (no cash paid) and is an award—not a market purchase or sale—intended as compensation and subject to future vesting and any exercise conditions.

Key Details

• Transaction date: 2026-09-08; reported on Form 4 filed 2026-09-09. Transaction type: Award/Grant (derivative).
• Amount: 950,000 shares; reported price: $0.00 (no immediate cash transfer).
• Vesting (per footnote): 25% of the shares vest on October 15, 2027; the remaining 75% vest in equal monthly installments through October 15, 2030.
• Shares owned after transaction: not specified in the filing.
• No 10b5-1 plan, tax-withholding sale, or late-filing indication disclosed in this Form 4.

Context This was a grant of an option-style equity award, so there is no immediate market transaction or realized cash value. Such awards are common executive compensation intended to align long-term incentives with shareholder value; the eventual benefit to the insider depends on future vesting and the company’s stock performance.